Covered recipient · General Payments record
KHALED JANOM
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2023–2024
$260.45
- Reported across 15 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $117.16 | 5 |
| Education | $59.91 | 6 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $63.11 | 2 |
| Retrophin, Inc. | $59.91 | 6 |
| Novo Nordisk AS | $40.96 | 2 |
| Ardelyx, Inc. | $13.09 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (11)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $29.36 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111608485 | CMS |
| Amgen Inc. | $33.75 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111608487 | CMS |
| Ardelyx, Inc. | $13.09 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146686729 | CMS |
| Novo Nordisk Inc | $13.12 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097306120 | CMS |
| Novo Nordisk Inc | $27.84 | 11/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097294629 | CMS |
| Travere Therapeutics, Inc. | $3.08 | 08/29/2024 | Education | Undisputed | 01/23/2026 | 1149960289 | CMS |
| Travere Therapeutics, Inc. | $3.08 | 08/29/2024 | Education | Undisputed | 01/23/2026 | 1149960296 | CMS |
| Travere Therapeutics, Inc. | $3.08 | 08/29/2024 | Education | Undisputed | 01/23/2026 | 1149960304 | CMS |
| Travere Therapeutics, Inc. | $16.89 | 08/29/2024 | Education | Undisputed | 01/23/2026 | 1149960309 | CMS |
| Travere Therapeutics, Inc. | $16.89 | 08/29/2024 | Education | Undisputed | 01/23/2026 | 1149960316 | CMS |
| Travere Therapeutics, Inc. | $16.89 | 08/29/2024 | Education | Undisputed | 01/23/2026 | 1149960322 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.